MGO One Seven LLC Purchases 128 Shares of Danaher Co. (NYSE:DHR)

MGO One Seven LLC boosted its holdings in Danaher Co. (NYSE:DHR) by 3.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,087 shares of the conglomerate’s stock after acquiring an additional 128 shares during the quarter. MGO One Seven LLC’s holdings in Danaher were worth $1,021,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Patrick M Sweeney & Associates Inc. boosted its position in shares of Danaher by 3.4% during the second quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock valued at $307,000 after buying an additional 40 shares during the last quarter. Trust Co of Kansas boosted its holdings in shares of Danaher by 4.1% during the 2nd quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock valued at $255,000 after acquiring an additional 40 shares during the last quarter. Abacus Planning Group Inc. grew its stake in shares of Danaher by 0.7% in the second quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock worth $1,359,000 after acquiring an additional 40 shares during the period. ST Germain D J Co. Inc. lifted its position in Danaher by 1.4% during the first quarter. ST Germain D J Co. Inc. now owns 2,880 shares of the conglomerate’s stock valued at $719,000 after purchasing an additional 41 shares during the period. Finally, Premier Path Wealth Partners LLC boosted its holdings in Danaher by 1.8% in the second quarter. Premier Path Wealth Partners LLC now owns 2,345 shares of the conglomerate’s stock worth $586,000 after purchasing an additional 42 shares during the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on DHR shares. Bank of America increased their price target on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Robert W. Baird raised their target price on Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Barclays upped their price target on shares of Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 24th. Evercore ISI cut their target price on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. Finally, Stifel Nicolaus increased their price target on shares of Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $278.94.

Insider Activity at Danaher

In other Danaher news, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the sale, the chief executive officer now owns 97,983 shares in the company, valued at approximately $27,435,240. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the sale, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Matthew Mcgrew sold 16,172 shares of the firm’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the transaction, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at $8,229,254.88. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 39,659 shares of company stock valued at $11,042,433. Corporate insiders own 11.10% of the company’s stock.

Danaher Price Performance

NYSE:DHR opened at $274.25 on Friday. The business’s 50-day simple moving average is $264.55 and its two-hundred day simple moving average is $256.49. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $281.70. The stock has a market cap of $198.07 billion, a PE ratio of 46.48, a P/E/G ratio of 4.48 and a beta of 0.83. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter last year, the company earned $2.05 EPS. The firm’s quarterly revenue was down 2.9% on a year-over-year basis. As a group, analysts forecast that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be given a dividend of $0.27 per share. The ex-dividend date is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.39%. Danaher’s dividend payout ratio is 18.31%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.